Objective-To assess whether intermittent transdermal treatment with glyceryl trinitrate causes clinically significant rebound in patients maintained on a blockers for stable angina pectoris.
Organic nitrates have been used effectively in the treatment of angina pectoris for over one hundred years.' Their short duration of action and rapid metabolism led to the development of slow release formulations and in 1982 a transdermal glyceryl trinitrate preparation was launched that provided continuous delivery of nitrate with constant plasma concentrations. 2 A problem of tolerance with continuous treatment was soon recognised, however, with loss of effect apparent within 24 hours. [3] [4] [5] [6] Although the mechanism of tolerance is not well understood it may be circumvented by implementing a nitrate free interval.7-'0 There is, however, evidence that intermittent regimes may predispose to anginal symptoms during the nitrate free interval,"-'3 the so called rebound phenomenon, possibly due to unopposed counter regulatory mechanisms. In these studies a significant number of patients were maintained on nitrates as the only treatment, which might have rendered them more susceptible to rebound during the nitrate free interval. Not uncommonly in clinical practice patients are maintained on a combination of treatments with nitrates and a ,B blocker, and potentially the problem of rebound may be lessened by this regime. This study was performed to look for evidence of rebound with serial exercise testing during nitrate withdrawal in patients also taking a fi blocker for stable angina pectoris.
Patients and methods

PATIENT SELECTION
Patients with stable angina who had had at least one positive treadmill exercise test (> 1 mm ST segment depression 80 ms after the J point) with associated chest pain were entered into the study. All patients were maintained on treatment with only a fi blocker throughout the trial, together with prophylactic glyceryl trinitrate (sublingual tablets or spray). Angiotensin converting enzyme inhibitors, diuretics, and aspirin were continued in 1, 3, and 6 patients respectively.
Exclusion criteria were women of child bearing age, myocardial infarction, or coronary bypass surgery within three months, unstable angina, nocturnal angina, exercise tolerance of <3 minutes on the modified Bruce protocol, glaucoma, relative hypotension (systolic blood pressure <100 mm Hg), or other contraindication to nitrate treatment, uncontrolled hypertension, overt heart failure, inadequate control on single treatment with a fi blocker, significant arrhythmias, or baseline electrocardiographic abnormalities that precluded interpretation of ST segment changes during exercise. All patients gave written informed consent in accordance with the guidelines established by the ethics committee of our hospital. PATIENT After the first exercise test on the next morning the patches were removed and replaced with either an active or a placebo patch. We looked for evidence of a rebound by comparing treadmill performance at 1 100 on placebo with the 1100 exercise test at the baseline visit. All patients tompleted both phases, during which they received both active and placebo patches after the 0900 exercise test.
CHARACTERISTICS
Patches were applied to a clean, dry, hairless area of the skin on the chest, avoiding areas of skin abrasion. The site was changed for subsequent patch application. Patients were asked about anginal symptoms and the presence of headache during the study period. The mean number of days between visits 1 and 2 was 6&6 (range 2-14) days and between visits 2 and 3 was 7 5 (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] days.
During the study all patients remained on a f blocker, which was not stopped on the study days. Glyceryl trinitrate tablets or spray were not permitted for at least one hour before exercise testing. Patients were asked not to smoke on the study days and were instructed to take a light early breakfast not less than two hours before the first exercise test. Beverages containing caffeine were not permitted after this time until after completion of both exercise tests on that day.
Treadmill testing was performed with the modified Bruce protocol. Those leads that best displayed ST segment depression by a computerised, signal averaged system (Marquette Case 15) were continuously monitored. A 12 lead electrocardiogram, heart rate, and cuff blood pressure were recorded at baseline and peak exercise, and at minute intervals. Time to angina, time to 1 mm ST segment depression (measured 80 ms after the J point), and total time were recorded and the rate-pressure product (heart rate x systolic blood pressure) at each of these times was found. Exercise was stopped at the level of discomfort at which the patient would usually stop, or earlier if the attending physician deemed it necessary. the smaller 25 mg patch before returning to hospital. Resting systolic blood pressure tended to be lower when on active treatment, but no compensatory tachycardia was noted, presumably due to concomitant ,B blockade. There were no significant adverse events and all patients completed the study.
BASELINE
Resting haemodynamics were similar for both exercise tests, and all patients were adequately fi blocked (mean resting heart rate < 60 beats/min).
TREATMENT DAY
On the treatment day active treatment was given during both 0900 and 1100 exercise tests. Resting heart rate and rate-pressure product were similar before both exercise (C)*p <001 vwithdrawal day 0900 and treatment day 1100; + p < 0 05 v treatment day 1100; ++ p<001v treatment day 1100. This transdermal delivery system was specifically designed to release nitroglycerin at a steady rate over a 24 hour period, thereby avoiding first pass inactivation by the liver and resulting in constant plasma concentrations. Although theoretically attractive, studies of delivery systems of transdermal nitrate showed that tolerance to the effect develops within 24 hours or earlier after topical application. [3] [4] [5] [6] [7] Strategies were developed to prevent tolerance, and nitrate free intervals are generally recommended. A nitrate free interval of 10 to 12 hours seems to be adequate and patients are usually advised to remove the patch during the night.8-10 '7 There is, however, concern that such a regime might cause a rebound effect during the nitrate free interval, especially with the transdermal delivery system where plasma concentrations decline rapidly upon removal of the patch.2 By contrast oral nitrates, particularly the slow release formulations, have a smoother pharmacokinetic profile that theoretically would be less likely to cause rebound.
There is evidence from munitions workers exposed to glyceryl trinitrate that subsequent withdrawal may cause symptoms. Lange et al described nine patients (from a group of 200 workers in a munitions factory) who showed non-atheromatous ischaemic heart disease induced by chronic industrial exposure to glyceryl trinitrate and subsequent withdrawal.'8 Reeves et 101721 22 These discrepancies may relate to the variability between studies with regard to the continuation or withdrawal of concomitant medication. Our patients had adequate fi blockade, in that they did not develop a reflex tachycardia with the hypotensive effects of patch application and there was no significant rise in systolic blood pressure with exercise.
LIMITATIONS
We did not include an additional visit with patients maintained on placebo patches before both exercise tests to exclude possible confounding effects of the placebo itself. All patients were maintained, however, on background antianginal treatment with a fi blocker that should minimise any placebo effect from the application patch. We also recognise the possibility of a type II error with the number of patients studied. The dose or duration of nitrate treatment may have been suboptimal. One patient had to remove the 25 mg patch due to unacceptable headache, and so underwent treadmill testing wearing the 50 mg patch. We did not perform a dose titration when initiating nitrate treatment, but there was a significant fall in resting systolic blood pressure before exercise testing in all three active phases, compared with the time controlled baseline test, suggesting that the nitrate dose was effective. We sought evidence of rebound at two hours after removal of the patch, so conceivably rebound could have occurred at an earlier or later time. The two hour assessment time was based on the known pharmacokinetic profile of the transdermal delivery system. All patients were studied with an overnight treatment period and a morning withdrawal period. Although different results might have been seen with an inverted schedule (day time treatment and evening withdrawal) the known circadian variation of angina would have predicted a greater chance of rebound in our study.
We 
